Low-grade serous ovarian cancer – a rare disease with more therapeutic options
Whilst high-grade serous cancers most commonly arise from the fimbrial end of the tube, having as marker gene p53 mutations, low-grade serous cancers are a different entity and should be seen distinct. Due to their slow growth and in parts development from serous borderline tumors, they show different genetic alterations and often marked estrogen-receptor expression (ER). This fact is now commonly used also therapeutically.
Anmelden und kostenlos alle Tools nutzen
Entdecken Sie das gesamte Angebot (z.B. Scores, Guidelines, Veranstaltungen, Drugshortages, Cochrane Library, Compendium)